| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
CO2
|
|
|
|
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
06 May 2011
Highlights: ► MiRNAs influence nearly all aspects of health and diseases, including cancer. ► Cancer cells have miRNAs aberrations (deregulated gene expression and mutations). ► MiRNA aberrations affe...
|
Elisa Giovannetti,
Ayse Erozenci,
Jorn Smit,
Romano Danesi,
Godefridus J. Peters
et al.
|
103-122
|
|
|
|
Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes
25 March 2011
Abstract: Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) might be crucial in comparing effectiveness of treatments as they could provide invaluable information to be...
|
F. Efficace,
K. Cocks,
M. Breccia,
M. Sprangers,
C.A. Meyers,
M. Vignetti,
M. Baccarani,
F. Mandelli,
GIMEMA and EORTC Quality of Life Group
et al.
|
123-135
|
|
|
|
Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors
20 April 2011
Abstract: In this article, we reviewed and quantified reporting of the risk of myelotoxicity, specifically febrile neutropenia (FN), and the related use of supportive care with colony-stimulating fact...
|
Arlene Chan,
Shailendra Verma,
Sibylle Loibl,
Jeffrey Crawford,
Mi Rim Choi,
Lyndah Dreiling,
Ted Vandenberg
et al.
|
136-150
|
|
|
|
The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?
09 March 2011
Abstract: Purpose: We address whether rational and significant clinical data exist on using angiogenic targeted therapies as neoadjuvant or adjuvant options to nephrectomy in non-metastatic RCC. Metho...
|
Alessandro Sciarra,
Susanna Cattarino,
Stefano Salciccia,
Andrea Alfarone,
Alessandro Gentilucci,
Ulderico Parente,
Gianna Mariotti,
Michele Innocenzi,
Vincenzo Gentile
et al.
|
151-162
|
|
|
|
Eribulin—A review of preclinical and clinical studies
15 April 2011
Abstract: Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have dem...
|
Umang Swami,
Imran Chaudhary,
Mohammad H. Ghalib,
Sanjay Goel
|
163-184
|
|
|
|
A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer
25 April 2011
Abstract: Primary malignant melanoma (MM) of the uterine cervix is an extremely rare neoplasm, with about 78 cases described in the literature. Since traces of melanocytes in normal cervical epitheliu...
|
Sara Pusceddu,
Emilio Bajetta,
Maria Luisa Carcangiu,
Barbara Formisano,
Monika Ducceschi,
Roberto Buzzoni
et al.
|
185-195
|
|
|
|
Comorbidity and survival after early breast cancer. A review
03 May 2011
Abstract: Introduction: Survival after breast cancer is determined by disease related factors such as stage at diagnosis, patient characteristics, e.g., age, and treatment. Aim: To review evidence pub...
|
Lotte Holm Land,
Susanne Oksbjerg Dalton,
Trine Lembrecht Jørgensen,
Marianne Ewertz
|
196-205
|
|
